Company Filing History:
2 out of 525 
1 out of 8 
Years Active: 1997-2000
Title: M W Visseren: Innovator in Cancer Immunotherapy
Introduction
M W Visseren is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative work on tumor rejection antigens.
Latest Patents
Visseren holds two patents, with his latest inventions focusing on isolated tumor rejection antigen precursor MAGE-2 derived peptides. These peptides are designed to bind with HLA-A2 molecules, creating complexes that provoke the production of cytolytic T cells (CTLs). The resulting CTLs are specific for the complexes of HLA-A2 and the peptide, which can be utilized to generate monoclonal antibodies. Additionally, he has developed new peptides derived from the MAGE-2 molecule that bind to HLA-A*0201 molecules, inducing CTL proliferation when complexed with their HLA partners.
Career Highlights
Throughout his career, M W Visseren has worked with prestigious institutions such as the Ludwig Institute for Cancer Research Limited and Leiden University. His research has focused on advancing the understanding of immunotherapy and its applications in treating cancer.
Collaborations
Visseren has collaborated with esteemed colleagues in the field, including Pierre Van Der Bruggen and Thierry R Boon-Falleur. Their joint efforts have contributed to the advancement of cancer treatment methodologies.
Conclusion
M W Visseren's innovative work in the development of tumor rejection antigen peptides has the potential to significantly impact cancer immunotherapy. His contributions to the field highlight the importance of research and collaboration in advancing medical science.